Medical articles today

/* 728x15, */

New MADIT II Clinical Info Conversation Shows Long-Term Survival Benediction For Implantable Defibrillator Therapy

/* 468x60, */

Boston Scientific Convention (NYSE: BSX) announced that an analysis of long-term facts from the MADIT II clinical recite demonstrates that the life-saving benefits of implantable cardioverter defibrillator (ICD) therapy remain sustainable at eight years. This is the anterior time long-term news get been presented regarding the life-saving benefits of ICDs in a important prevention population. The analysis was presented during a late-breaking session at the Heart Rhythm Country Scientific Sessions in Boston.
The analysis shows a sustainable mortality benefit over time, including:
-- At eight years, one vitality is saved for every six patients who receive an ICD. This represents a significant improvement over the two-year MADIT II data, which showed one being saved for every 17 patients.
-- A 41 percent relative discount in the risk of death for ICD patients at four years
-- A 37 percent relative lowering in the risk of annihilation for ICD patients at eight years
The MADIT II study, sponsored remarkably by Boston Scientific, was designed to clinch whether ICDs improve survival when compared to drug therapy alone in feelings assailment survivors with moderate impairment of the left ventricle, the heart's main pumping chamber. Initial results published in the Advanced Great britain Journal of Medicine (March 21, 2002) demonstrated that ICD therapy reduced the relative risk of death by 31 percent at 20 months follow-up.
"ICD therapy has proved effective in patients at risk of sudden cardiac death, and nowadays the long-term MADIT II data present the life-saving benefits of these devices carry forward over time," said Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester Medical Center and Principal Investigator of the MADIT, MADIT II and MADIT-CRT trials.
"We are proud to have been the exclusive sponsor of landmark trials coextensive MADIT II," said Fred Colen, President, Boston Scientific Cardiac Rhythm Management. "More than 80 percent of U.S. patients who appropriate an ICD or CRT-D were fundamental indicated for this life-saving therapy on ice Boston Scientific clinical research."(1)
Cautionary Statement Regarding Forward-Looking Statements
This press proceeds contains forward-looking statements within the doctrine of Divide 21E of the Securities Change Fact of 1934. Forward-looking statements may be identified by text like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and coincidental words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of fated events or performance. These forward-looking statements include, among other things, statements regarding our product performance, clinical outcomes, regulatory approval of our products, and our life strategy. Whether our underlying assumptions turn outside to be incorrect, or provided undeniable risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the ultimate (together with other factors) could affect our ability to contraption our employment strategy and may foundation actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to area undue reliance on any of our forward-looking statements.
Factors that may determinant such differences include, among other things: booked economic, competitive, reimbursement and regulatory conditions; advanced product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, eventual business decisions made by us and our competitors. All of these factors are galling or impossible to predict accurately and alive with of them are beyond our control. For a also list and discription of these and other extensive risks and uncertainties that may change our final operations, gape Bite I, Item 1A- Risk Factors in our most original Annual Report on Articulation 10-K filed with the Securities and Exchange Commission, which we may renew in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or testament file thereafter. We disclaim any basis or debt to publicly update or revise any forward-looking statements to copy any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may prevail the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
(1) Trials include MADIT, MADIT II, CONTAK-CD, and COMPANION.
Source: Boston Scientific Corporation
/* 468x60, */


statements, statements factors, statements cautionary, statements copy, statements expressed, statements contained, statements doctrine, statements press, statements based, statements identified
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy